The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-approves-monthly-dosing-rybrevant-faspro-nsclc-2026a1000570?src=rss
Author :
Publish date : 2026-02-18 21:03:00
Copyright for syndicated content belongs to the linked Source.
